Table 3.

Review of PCOS prevalence in girls with precocious puberty before, during or after treatment with GnRHa

Authors and references	Results
Boepple PA. In: Savage MO, Bourguignon J-P, Grossman AB, eds. Frontiers in paediatric neuroendocrinology. Oxford, London,Edinburgh, Cambridge, Carlton: Blackwell. 1994: pp. 23-9.	PCOS was reported in approximately half of the patients treated with GnRHa.
Bridges NA et al. Clin Endocrinol (Oxf) 1995; 42: 135-40.	The prevalence of PCOS among CPP patients was 24%, compared with 2% in an age-matched control group.
Lazar L et al. Eur J Endocrinol. 1995; 133: 4036.	A significant number of girls with CPP develop PCO-like syndrome at a relatively young age.
Baek-Jensen AM et al. J Pediatr.1998; 132:105-8	The Authors did not observe PCOS during or after treatment with GnRHa.
Heger S et al. J Clin Endocrinol Metab.1999; 84:4583-90.	No increased incidence of PCOS in GnRHa-treated patients with CPP compared with the normal population was reported.
Chiavaroli V et al. Eur J Endocrinol. 2010;163:55-62.	The prevalence of PCOS and hyperandrogenemia was significantly higher in GNRHa-treated adolescents than in untreated adolescents (36 and 14.5% respectively, P=0.04; 56 and 23.6% respectively, P=0.01).
Magiakou MA et al. J Clin Endocrinol Metab. 2010;95:109-17.	21% of subjects evaluated between ages 16 and 32 had PCOS, using the National Institutes of Health criteria.